ISRCTN69546136已完成未知
Randomised phase II study of sequentially high dose Methotrexate and Fluorouracil combined with Epirubicin (FEMTX) versus FEMTX plus Cisplatin (FEMTX-P) in advanced gastric cancer
Pharmacia Ltd & Upjohn (UK)0 个研究点目标入组 0 人开始时间: 2002年8月19日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1. Aged less than 70 years
- •2. Histologically confirmed locally advanced and/or metastatic gastric cancer
- •3. Measurable or evaluable disease
- •4. Karnofsky status 80-100
- •5. Adequate renal, hepatic and bone marrow function
排除标准
- •1. Previous chemotherapy or radiotherapy
- •2. Pleural or peritoneal effusions which cannot be adequately drained
- •3. Central Nervous System (CNS) metastases
- •4. History of previous or concomitant malignancy except squamous or basal cell carcinoma of the skin which has been effectively treated and carcinoma in situ of the cervix which has been treated operatively only
- •5. Other medical contraindications to treatment protocols
研究者
相似试验
招募中
2 期
A randomized phase II study of pulsatile high-dose sunitinib versus TAS-102 in patients with metastatic colorectal carcinoma (mCRC).metastatic colorectal carcinoma1001799010017991NL-OMON53126Radboud Universitair Medisch Centrum70
招募中
不适用
A randomized phase II study of pulsatile high-dose sunitinib versus TAS-102 in patients with metastatic colorectal carcinoma (mCRC).NL-OMON27160Radboud UMC60
招募中
1 期
Clinical Study of High-Dose Treosulfan/Melphalan as Consolidation Treatment in Newly Diagnosed High-Risk and Very High-Risk Ewing SarcomaMedDRA version: 20.0Level: PTClassification code 10015560Term: Ewing's sarcomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Ewing SarcomaEUCTR2023-000169-14-ITFondazione Santobono Pausilipon ONLUS60
已完成
2 期
Randomized Phase II Study Comparing Dose Escalated Weekly Paclitaxel versus Standard Dose Weekly Paclitaxel for Patients with Previously Treated Advanced Gastric CancerJPRN-UMIN000004055Aichi Cancer Center Hospital90
已完成
2 期
A Phase 1/2 Multiple-Ascending-Dose Study With a Long-Term Open-Label Extension to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Effect on Disease Progression of BIIB105 Administered Intrathecally to Adults With Amyotrophic Lateral Sclerosis With or Without PolyCAG Expansion in the ATXN2 GeneAmyotrophic lateral sclerosis (ALS)neurodegenerative disease10029317NL-OMON52649Biogen10